Niagen Bioscience, Inc.
NAGE· Nasdaq
NAGENiagen Bioscience, Inc.
Filed Mar 10, 2020 · 10-K · 70 days after period end · 0001654954-20-002437
derived · Computed from the longer spans the company filed.
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $13.09M | $9.07M | $7.53M | $4.45M |
| Net Income | -$8.85M | -$8.22M | -$8.82M | -$2.15M |
| EPS Diluted | — | — | -$0.17 | -$0.06 |
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2019 · filed Mar 10, 2020 · 70 d after period end
